TRF2 as novel marker of tumor response to taxane-based therapy: from mechanistic insight to clinical implication

TRF2 as novel marker of tumor response to taxane-based therapy: from mechanistic insight to clinical implication

Abstract Background Breast Cancer (BC) can be classified, due to its heterogeneity, into multiple subtypes that differ for prognosis and clinical management. Notably, triple negative breast cancer (TNBC) – the most aggressive BC form – is refractory to endocrine and most of the target therapies. In...

Full description

Bibliographic Details
Main Authors: Sara Iachettini, Irene Terrenato, Manuela Porru, Serena Di Vito, Angela Rizzo, Carmen D’Angelo, Eleonora Petti, Roberto Dinami, Carmen Maresca, Anna Di Benedetto, Aldo Palange, Antonino Mulè, Angela Santoro, Antonella Palazzo, Paola Fuso, Antonella Stoppacciaro, Patrizia Vici, Lorena Filomeno, Francesca Sofia Di Lisa, Teresa Arcuri, Eriseld Krasniqi, Alessandra Fabi, Annamaria Biroccio, Pasquale Zizza
Format: Article
Language:English
Published: BMC 2024-03-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
TRF2
Autophagy
Taxanes
Drug sensitivity
TNBC
Predictive marker
Online Access:https://doi.org/10.1186/s13046-024-02998-w

Internet

https://doi.org/10.1186/s13046-024-02998-w

Similar Items